Sudo Scores $37M to Advance TYK2 Inhibitors Into Clinical Testing for AS
Sudo Biosciences has secured $37 million in series A financing to back the development of TYK2 inhibitors as potential anti-inflammatory medicines for immune-mediated inflammatory conditions, such as ankylosing spondylitis (AS). The goal, the company said in a press release announcing the new funding, is to move the…